Yes, it has been discussed a little not a lot. See this message and this message.

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/712700-abca1-overexpression-worsens-colorectal-cancer-prognosis-and-this-can-be-ameliorated-by-apabetalone/messages/2202805#message

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/712700-abca1-overexpression-worsens-colorectal-cancer-prognosis-and-this-can-be-ameliorated-by-apabetalone/messages/2202824#message

On a side note, slide 57 listed a whole bunch of adverse event classes but didn't list any oncology related indications. So the jury is still out on whether there was any effect of apabetalone on cancer, including colorectal cancer. Sometimes, clinical trials have surprise benefits. Just recently, CANTOS cardiovascular outcomes trial for Novartis's anti-IL-1B antibody canakinumab found significantly less lung cancer in the patients treated w/ canakinumab. So there may be surprises yet to come with BETonMACE.

https://www.thelancet.com/journals/lancet/article/PIIS0140-67361732247-X/fulltext

As another side note, looks like Novartis is gearing up for a $7 billion buyout of The Medicine's Company for the inclisiran PCSK9 RNAi drug. $85 per share for MDCO is the rumor (not finalized yet). Article says deal is worth close to $10 billion using a fully diluted share count. And this is without a completed CVOT or approved drug. The MDCO Orion LDL-C Phase 3 lowering program just wrapped up and NDA/MAA applications to FDA/EMA havne't even been submitted yet.

https://www.wsj.com/articles/novartis-nears-deal-to-buy-cholesterol-drug-maker-medicines-co-11574535418

BDAZ